person · Reporting owner

Parks Diane L.

Disclosed activity across 4 companies

Tapewire entity: 41322
SEC CIK: 0001781026

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Celularity IncCELU · Entity 7145	Director	January 12, 2026	January 15, 2026
Kura Oncology, Inc.KURA · Entity 4871	Director	June 04, 2026	June 04, 2026
SOLIGENIX, INC.SNGX · Entity 8067	Director	October 12, 2026	October 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Celularity Inc

Report date January 12, 2026 · Filed January 15, 2026 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	520,021	Reported balance After 2026-01-12 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2026-01-12 · Grant · Acquired 30,000 · Balance 520,021 F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. F2: Includes 30,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.

Filing footnotes · ownership attribution and instrument terms

F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.

F2: Includes 30,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant.

Kura Oncology, Inc.

Report date June 04, 2026 · Filed June 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $8.77 · Expires 2036-06-03	Direct	35,000	Reported balance After 2026-06-04 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-04 · Grant · Acquired 35,000 · Balance 35,000 F1: This option vests in full on the one year anniversary of the date of grant.

Filing footnotes · ownership attribution and instrument terms

F1: This option vests in full on the one year anniversary of the date of grant.

SOLIGENIX, INC.

Report date October 12, 2026 · Filed October 13, 2026

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $208.80 · Expires 2029-07-07	Direct	Reported balance After 2026-10-12 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-10-12 · Disposition to issuer · Disposed 6 · Balance 0 F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 566 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $232.80 · Expires 2029-09-05	Direct	Reported balance After 2026-10-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-10-12 · Disposition to issuer · Disposed 128 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $422.40 · Expires 2029-07-07	Direct	Reported balance After 2026-10-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-10-12 · Disposition to issuer · Disposed 56 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $472.80 · Expires 2030-09-15	Direct	Reported balance After 2026-10-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-10-12 · Disposition to issuer · Disposed 63 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $247.20 · Expires 2031-09-22	Direct	Reported balance After 2026-10-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-10-12 · Disposition to issuer · Disposed 121 · Balance 0
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $156.00 · Expires 2032-11-16	Direct	Reported balance After 2026-10-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-10-12 · Disposition to issuer · Disposed 192 · Balance 0

Filing footnotes · ownership attribution and instrument terms

F1: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 566 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CTI BIOPHARMA CORP

Report date June 26, 2023 · Filed June 26, 2023

Section 16 reporting ended · disclosed 2023-06-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74	Direct	Reported balance After 2023-06-26 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-06-26 · Disposition to issuer · Disposed 120,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.49	Direct	Reported balance After 2023-06-26 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08	Direct	Reported balance After 2023-06-26 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-06-26 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes)

F2: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 12, 2026 Filed Oct 13, 2026 14:08 UTC	SOLIGENIX, INC. SNGX · Entity 8067	Disposition to issuerStock Option (Right to Buy) · Derivative	192	$0.00 Strike: $156.00	$0.00	Disclosure SEC source: 0001781026-26-000004 · form4-10132026_021044.xml · derivative · entry 6 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 192 shares Expires 2032-11-16 Read SEC document
October 12, 2026 Filed Oct 13, 2026 14:08 UTC	SOLIGENIX, INC. SNGX · Entity 8067	Disposition to issuerStock Option (Right to Buy) · Derivative	121	$0.00 Strike: $247.20	$0.00	Disclosure SEC source: 0001781026-26-000004 · form4-10132026_021044.xml · derivative · entry 5 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 121 shares Expires 2031-09-22 Read SEC document
October 12, 2026 Filed Oct 13, 2026 14:08 UTC	SOLIGENIX, INC. SNGX · Entity 8067	Disposition to issuerStock Option (Right to Buy) · Derivative	63	$0.00 Strike: $472.80	$0.00	Disclosure SEC source: 0001781026-26-000004 · form4-10132026_021044.xml · derivative · entry 4 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 63 shares Expires 2030-09-15 Read SEC document
October 12, 2026 Filed Oct 13, 2026 14:08 UTC	SOLIGENIX, INC. SNGX · Entity 8067	Disposition to issuerStock Option (Right to Buy) · Derivative	56	$0.00 Strike: $422.40	$0.00	Disclosure SEC source: 0001781026-26-000004 · form4-10132026_021044.xml · derivative · entry 3 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56 shares Expires 2029-07-07 Read SEC document
October 12, 2026 Filed Oct 13, 2026 14:08 UTC	SOLIGENIX, INC. SNGX · Entity 8067	Disposition to issuerStock Option (Right to Buy) · Derivative	128	$0.00 Strike: $232.80	$0.00	Disclosure SEC source: 0001781026-26-000004 · form4-10132026_021044.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128 shares Expires 2029-09-05 Read SEC document
October 12, 2026 Filed Oct 13, 2026 14:08 UTC	SOLIGENIX, INC. SNGX · Entity 8067	Disposition to issuerStock Option (Right to Buy) · Derivative	6	$0.00 Strike: $208.80	$0.00	Disclosure SEC source: 0001781026-26-000004 · form4-10132026_021044.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6 shares Expires 2029-07-07 F1 · kind: On October 12, 2026, the Reporting Person voluntarily surrendered stock options exercisable for an aggregate of 566 shares of Common Stock with exercise prices set forth in the table above to the Issuer for cancellation for no consideration. The cancellation is exempt from Section 16(b) of the Exchange Act pursuant to Rule 16b-3(e) and Rule 16b-6(d), and exempt from the reporting requirements of Section 16(a) pursuant to Rule 16a-4(d). The Reporting Person is voluntarily reporting this transaction. Read SEC document
September 17, 2026 Filed Sep 18, 2026 20:11 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	78,947	$0.00 Strike: $0.38	$0.00	Disclosure SEC source: 0001781026-26-000002 · form4-09182026_080934.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,947 Underlying: Common Stock · 78,947 shares Expires 2036-09-16 F1 · derivative.exercise_date: The stock option vests ratably on each of December 17, 2026, March 17, 2027, June 17, 2027 and September 17, 2027. Read SEC document
June 04, 2026 Filed Jun 4, 2026 22:30 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	35,000	$0.00 Strike: $8.77	$0.00	Disclosure SEC source: 0001193125-26-257903 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-06-03 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
January 12, 2026 Filed Jan 15, 2026 01:51 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001493152-26-002297 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,021 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 30,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
January 12, 2026 Filed Jan 15, 2026 21:15 UTC Amendment	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	30,000	$0.00	$0.00	Disclosure SEC source: 0001493152-26-002427 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 520,021 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. F2 · balance_after: Includes 30,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest immediately upon grant. Read SEC document
December 29, 2025 Filed Dec 30, 2025 21:30 UTC	Celularity Inc CELU · Entity 7145	GrantStock Options · Derivative	156,250	$0.00 Strike: $1.20	$0.00	Disclosure SEC source: 0001493152-25-029615 · ownership.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 518,774 Underlying: Class A Common Stock · 156,250 shares Expires 2035-12-29 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
December 29, 2025 Filed Dec 30, 2025 21:30 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	125,000	$0.00	$0.00	Disclosure SEC source: 0001493152-25-029615 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 490,021 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 125,000 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
December 19, 2025 Filed Dec 22, 2025 21:30 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	67,416	$0.00	$0.00	Disclosure SEC source: 0001493152-25-028787 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,021 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs vested and became exercisable on December 19, 2025. Read SEC document
November 19, 2025 Filed Nov 21, 2025 21:17 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	61,539	$0.00	$0.00	Disclosure SEC source: 0001493152-25-024634 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 365,021 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the date of grant. Read SEC document
June 20, 2025 Filed Jun 20, 2025 20:25 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	17,647	$0.00 Strike: $1.70	$0.00	Disclosure SEC source: 0001415889-25-017855 · form4-06202025_080640.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,647 Underlying: Common Stock · 17,647 shares Expires 2035-06-20 F1 · derivative.exercise_date: The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026. Read SEC document
June 05, 2025 Filed Jun 6, 2025 20:05 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	28,500	$0.00 Strike: $6.57	$0.00	Disclosure SEC source: 0000950170-25-083040 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2035-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
December 19, 2024 Filed Jan 7, 2025 21:05 UTC	Celularity Inc CELU · Entity 7145	GrantStock Option (Right to Buy) · Derivative	84,746	$0.00 Strike: $2.23	$0.00	Disclosure SEC source: 0001493152-25-001221 · ownership.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 362,524 Underlying: Class A Common Stock · 84,746 shares Expires 2034-12-19 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
December 19, 2024 Filed Jan 7, 2025 21:05 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	67,416	$0.00	$0.00	Disclosure SEC source: 0001493152-25-001221 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,482 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
December 12, 2024 Filed Dec 13, 2024 22:37 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	8,646	$0.00 Strike: $3.47	$0.00	Disclosure SEC source: 0001415889-24-029351 · form4-12132024_101244.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,646 Underlying: Common Stock · 8,646 shares Expires 2034-12-12 F1 · derivative.exercise_date: The stock option vests ratably on each of March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. Read SEC document
June 05, 2024 Filed Jun 7, 2024 20:30 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	26,000	$0.00 Strike: $21.79	$0.00	Disclosure SEC source: 0000950170-24-070700 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
December 15, 2023 Filed Dec 15, 2023 21:10 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	38,136	$0.00 Strike: $0.59	$0.00	Disclosure SEC source: 0001415889-23-016528 · form4-12152023_041208.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,136 Underlying: Common Stock · 38,136 shares Expires 2033-12-14 F1 · derivative.exercise_date: The stock option vests ratably on each of March 15, 2024, June 15, 2024, September 15, 2024 and December 15, 2024. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	80,000	Not disclosed Strike: $4.08	Not disclosed	Disclosure SEC source: 0000899243-23-016483 · doc4.xml · derivative · entry 3 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	80,000	Not disclosed Strike: $4.49	Not disclosed	Disclosure SEC source: 0000899243-23-016483 · doc4.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 26, 2023 Filed Jun 26, 2023 16:05 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	Disposition to issuerStock Option (Right to Buy) · Derivative	120,000	Not disclosed Strike: $2.74	Not disclosed	Disclosure SEC source: 0000899243-23-016483 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 120,000 shares Expires not disclosed F1 · price: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · price: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.exercise_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. F1 · derivative.expiration_date: Pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 10, 2023, by and among the Issuer, Swedish Orphan Biovitrum AB (publ) ("Parent"), and Cleopatra Acquisition Corp., an indirect wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of June 26, 2023 (the "Effective Time"), each option to purchase shares of Company Common Stock that was outstanding immediately prior to the Effective Time, whether or not vested, with an exercise price that was less than the Offer Price, terminated and was cancelled immediately prior to the Effective Time and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) F2 · derivative.expiration_date: (Continued from Footnote 1) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option. Read SEC document
June 14, 2023 Filed Jun 17, 2023 01:04 UTC	Celularity Inc CELU · Entity 7145	GrantStock Option (Right to Buy) · Derivative	277,778	$0.00 Strike: $0.75	$0.00	Disclosure SEC source: 0000899243-23-015882 · doc4.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,778 Underlying: Class A Common Stock · 277,778 shares Expires 2033-06-14 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
June 14, 2023 Filed Jun 17, 2023 01:04 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	199,921	$0.00	$0.00	Disclosure SEC source: 0000899243-23-015882 · doc4.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 236,066 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 199,921 RSUs granted under the. 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, June 14, 2023, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
May 31, 2023 Filed Jun 2, 2023 20:57 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	26,000	$0.00 Strike: $13.32	$0.00	Disclosure SEC source: 0001209191-23-033871 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
April 05, 2023 Filed Apr 7, 2023 18:20 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	GrantStock Option (right to buy) · Derivative	80,000	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0000899243-23-010982 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2033-04-05 F1 · derivative.exercise_date: This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2024 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document
November 17, 2022 Filed Nov 21, 2022 21:31 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	46,154	$0.00 Strike: $0.65	$0.00	Disclosure SEC source: 0001415889-22-011630 · form4-11212022_091115.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,504 Underlying: Common Stock · 46,154 shares Expires 2032-11-16 F1 · derivative.exercise_date: The stock option vests ratably on each of February 17, 2023, May 17, 2023, August 17, 2023 and November 17, 2023. Read SEC document
July 13, 2022 Filed Jul 16, 2022 00:52 UTC	Celularity Inc CELU · Entity 7145	GrantStock Option (Right to Buy) · Derivative	54,152	$0.00 Strike: $4.15	$0.00	Disclosure SEC source: 0000899243-22-026193 · doc4.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,152 Underlying: Class A Common Stock · 54,152 shares Expires 2032-07-13 F2 · derivative.exercise_date: This option is granted under the Issuer's 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
July 13, 2022 Filed Jul 16, 2022 00:52 UTC	Celularity Inc CELU · Entity 7145	GrantClass A Common Stock	36,145	$0.00	$0.00	Disclosure SEC source: 0000899243-22-026193 · doc4.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,145 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs is shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, July 13, 2022, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document
June 21, 2022 Filed Jun 23, 2022 20:52 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	23,000	$0.00 Strike: $14.84	$0.00	Disclosure SEC source: 0001209191-22-038931 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2032-06-20 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
June 02, 2022 Filed Jun 4, 2022 01:22 UTC	Celularity Inc CELU · Entity 7145	GrantStock Option (Right to Buy) · Derivative	42,413	$0.00 Strike: $10.37	$0.00	Disclosure SEC source: 0000899243-22-021123 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,413 Underlying: Class A Common Stock · 42,413 shares Expires 2032-06-02 F1 · derivative.exercise_date: This option shall vest and become exercisable in three successive equal annual installments so that the option is vested in full on the three-year anniversary of the grant date, and subject to the Reporting Person's continuous service on each vesting date. Read SEC document
March 09, 2022 Filed Mar 11, 2022 19:46 UTC	CTI BIOPHARMA CORP CTIC · Entity 111865	GrantStock Option (right to buy) · Derivative	80,000	$0.00 Strike: $4.49	$0.00	Disclosure SEC source: 0000899243-22-010779 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: This stock option vests on the first to occur of (i) the date that is twelve months after the date of grant, and (ii) immediately prior to the first annual meeting of the Company's stockholders in 2023 at which one or more members of the Company's Board of Directors are to be elected, subject to the Reporting Person's continued service through such date or event. Read SEC document
September 23, 2021 Filed Sep 24, 2021 20:02 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	29,126	$0.00 Strike: $1.03	$0.00	Disclosure SEC source: 0001104659-21-119283 · tm2128426-1_4seq1.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,126 Underlying: Common Stock · 29,126 shares Expires 2031-09-22 F1 · security: The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022. F1 · derivative.exercise_date: The stock option vests ratably on each of December 23, 2021, March 23, 2022, June 23, 2022 and September 23, 2022. Read SEC document
June 22, 2021 Filed Jun 23, 2021 21:21 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	23,000	$0.00 Strike: $21.54	$0.00	Disclosure SEC source: 0001209191-21-042790 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
September 16, 2020 Filed Sep 18, 2020 20:35 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	15,228	$0.00 Strike: $1.97	$0.00	Disclosure SEC source: 0001213900-20-027372 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,228 Underlying: Common Stock · 15,228 shares Expires 2030-09-15 F1 · security: The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021. F1 · derivative.exercise_date: The stock option vests ratably on each of December 16, 2020, March 16, 2021, June 16, 2021 and September 16, 2021. Read SEC document
June 24, 2020 Filed Jun 26, 2020 20:11 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	23,000	$0.00 Strike: $17.97	$0.00	Disclosure SEC source: 0001209191-20-039076 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
June 18, 2020 Filed Jun 19, 2020 20:30 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	13,500	$0.00 Strike: $1.76	$0.00	Disclosure SEC source: 0001213900-20-015362 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: COMMON STOCK · 13,500 shares Expires 2029-07-07 Read SEC document
October 14, 2019 Filed Oct 16, 2019 20:07 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	8,666	$0.00 Strike: $13.78	$0.00	Disclosure SEC source: 0001209191-19-053278 · doc4.xml · derivative · entry 2 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,666 Underlying: Common Stock · 8,666 shares Expires 2029-10-13 F2 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document
October 14, 2019 Filed Oct 16, 2019 20:07 UTC	Kura Oncology, Inc. KURA · Entity 4871	GrantOption to purchase common stock · Derivative	30,000	$0.00 Strike: $13.78	$0.00	Disclosure SEC source: 0001209191-19-053278 · doc4.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-10-13 F1 · derivative.exercise_date: This option vests in three equal annual installments commencing on the one year anniversary of the date of grant. Read SEC document
September 23, 2019 Filed Sep 23, 2019 23:15 UTC	SOLIGENIX, INC. SNGX · Entity 8067	PurchaseCommon Stock	14,940	$0.93	$13,870.30	Disclosure SEC source: 0001213900-19-018706 · ownership.xml · nonDerivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,940 F1 · price: This transaction was executed in multiple trades at prices ranging from $0.9273 to $0.93. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document
September 06, 2019 Filed Sep 10, 2019 22:38 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	30,928	$0.00 Strike: $0.97	$0.00	Disclosure SEC source: 0001213900-19-017652 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,928 Underlying: Common Stock · 30,928 shares Expires 2029-09-05 F1 · security: The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020. F1 · derivative.exercise_date: The stock option vests ratably on each of December 6, 2019, March 6, 2020, June 6, 2020 and September 6, 2020. Read SEC document
July 08, 2019 Filed Jul 8, 2019 23:51 UTC	SOLIGENIX, INC. SNGX · Entity 8067	GrantStock Option (Right to Buy) · Derivative	1,500	$0.00 Strike: $0.87	$0.00	Disclosure SEC source: 0001213900-19-012261 · ownership.xml · derivative · entry 1 Parks Diane L. · CIK 0001781026 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: COMMON STOCK · 1,500 shares Expires 2029-07-07 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.